

ASX Release

**Annual General Meeting
Chairman's Address**

Good morning ladies and gentlemen, welcome and thank-you for joining our 2021 AGM. My name is Sue MacLeman and I am Chair of TALi Digital.

Healthier, happier minds have huge benefits for children, families and society.

TALi is a digital therapeutics business, with a patented evidence-based platform technology that is designed to treat cognitive inattention.

Our initial target population is the early childhood segment where the Company has commercialised digital game-based attention screening and training programs – known collectively as TALi.

The Company has a multi-layered strategy to reach our customers, with a number of channels to market for our technology platform, across a range of global markets.

In August we announced a highly transformative landmark agreement with Akili Interactive Labs that will open up the prescription healthcare channel in the US, the world's largest market for childhood ADHD treatment.

Our Managing Director, Glenn Smith will talk to this Strategic Licencing Agreement during his address, however I do want to highlight that this agreement, with a partner of Akili's standing, validates the high quality and scientific rigour that sits behind our core TALi technology.

Over the year we have also focussed on the continued strengthening of our go-to-market leadership, and commercial roll-out, with the initiation of marketing campaigns in India as well as refreshed marketing plans for Australia, New Zealand and Singapore.

With the worst of the COVID-19 pandemic now behind us due to the success of vaccination programs, we believe that the markets I have just mentioned offer significant potential for our Company, and now is the appropriate time to accelerate our growth plans.

While we are in the early stages of our global expansion and commercial roll-out, our recent entry into the US puts us in an advantageous position in local markets. We expect to be able to announce further milestones in the forward periods.

We also continue to explore new clinical indications and the potential for our core TALi technology to deliver benefits to patients, particularly as we look to expand our reach and impact into broader age groups. We are engaged in evaluating a research program to explore TALi's applicability to other cognitive decline indications, more common in older age groups such as Mild Cognitive Impairment, which is often a precursor to Alzhiemers. We will have more to say about developments in this area early next year.

As we move into a new and exciting period for our Company we begin FY22 in a solid position. We are making good progress on our path towards building a base of sustainable long-term revenues for our shareholders.

From a funding and cash flow perspective, and as we stand today, we have approximately 4 quarters of cash available to fund our operations and commercialisation strategy.

Before I hand over to Glenn for his presentation, I would like to acknowledge our management team and the entire TALi Digital workforce for their commitment and drive during what has been a challenging twelve months, as we have all continued to manage the impacts of COVID-19 on our personal and professional lives.

I would also like to thank my fellow Board members for their ongoing commitment and guidance. Finally, thank-you to our shareholders who continue to support our Company in its growth journey.

We look forward to sharing further updates with you as we execute further initiatives into 2022.

Release authorised by:

TALi Digital Limited Board of Directors

CONTACT

Corporate

Glenn Smith
TALi Digital Managing Director
1300 082 013
investors@talidigital.com

Investors

Bellevue Investor Relations
Katie Mackenzie
0455 502 197
kmackenzie@bellevueir.com.au

Catherine Ross
0421 997 481
catherine@irconsult.com.au

About TALi Digital

TALi [TALi Digital Limited (ASX: TD1)] is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence and game-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy and places TALi at the forefront of patient experience and early intervention for attention related conditions. We believe in healthy, happier minds – they start here with TALi.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI has been found to often be a precursor to recognizing Alzheimer's disease and other forms of dementia). At TALi, our vision is to deliver a personalised digital experience to enhance cognitive care. Learn more at talidigital.com.